Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

FDA Clears Path for Disc Medicine's Bitopertin Resubmission

Disc Medicine has reached an agreement with the FDA to resubmit its rare blood disorder drug, bitopertin, for erythropoietic protoporphyria. This follows a rejection in February 2026 and allows the use of the current Phase 3 APOLLO trial to support a new regulatory filing. BMO Capital Markets views this as a "noted positive," potentially clearing the path for full approval, with a decision anticipated by mid-2027. The previous rejection was primarily due to concerns over the adequacy of a surrogate endpoint used in an earlier Phase 2 trial.

• FDA Agreement and Resubmission Path: Disc Medicine has secured an agreement with the FDA to resubmit its application for bitopertin, a drug for erythropoietic protoporphyria. This follows a previous rejection and provides a "clear path" to a full approval submission, according to BMO Capital Markets. The FDA's willingness to accept data from the ongoing Phase 3 APOLLO trial for the resubmission is a crucial step, potentially leading to a mid-2027 decision.
• Previous Regulatory Setback and Reasons: Bitopertin faced an FDA rejection in February 2026 for erythropoietic protoporphyria, despite having received a Commissioner’s National Priority Voucher in October 2025, which typically shortens review times significantly. The primary reason for the rejection was the FDA's questioning of the adequacy of the surrogate endpoint (percent change in whole-blood metal-free protoporphyrin IX) used in Disc's Phase 2 trial as a reliable predictor of clinical benefit. Allegations of interference from former CBER director Vinay Prasad also surrounded the initial review.
• Strategic Role of APOLLO Phase 3 Trial: The FDA's rejection letter explicitly required an adequate and well-controlled Phase 3 trial measuring clinical outcomes, rather than indicators. The APOLLO study, which Disc had already initiated but not included in its original application, now directly addresses these requirements. The recent FDA meeting confirmed that APOLLO "ticks these boxes," making its successful completion and data crucial for supporting a full approval for bitopertin and overcoming the previous endpoint concerns.

Bitopertin's Regulatory Path: Addressing EPP Endpoint Concerns

Clinical trials in erythropoietic protoporphyria (EPP) primarily utilize patient-reported outcome measures (PROMs) that capture the unique symptomatology and quality of life impacts of this rare photodermatosis. The Sunlight Exposure Diary and the EPP Impact Questionnaire (EPIQ) represent recently developed, disease-specific instruments designed to comprehensively assess all aspects of EPP and X-linked protoporphyria (XLP), including both symptoms and their broader impacts on patients' lives. These PROMs specifically evaluate the duration, severity, and impact of early warning symptoms and full phototoxic reactions while capturing the effects on well-being and health-related quality of life.

Exploratory Factor Analysis has provided important insights into the psychometric structure of these instruments. The Sunlight Exposure Diary demonstrated one underlying factor focused on Tingling/Itching symptoms, with evaluation typically centered on a single item: Daily Daylight Tolerance Over 2-Week Interval. The EPIQ revealed three distinct factors—Duration of Full Reaction, Overall Change, and Overall Severity and Impact—all of which demonstrated acceptable to strong psychometric properties across reliability measures (internal consistency, test-retest), validity assessments (construct, known groups), and responsiveness metrics. Ranges for meaningful change have been established using both anchor- and distribution-based approaches to ensure clinical relevance.

The endpoint landscape is further enriched by additional standardized instruments including PROMIS-57 v2.1, PROMIS Short Form v2.0 - Social Isolation, and PROMIS-Neuropathic Pain Quality v2.0 scales. However, a significant challenge emerges from the heterogeneity in outcome measures across trials evaluating different pharmacotherapies such as afamelanotide, dersimelagon, bitopertin, and cimetidine. This variability in endpoints, combined with differences in patient populations across studies, substantially limits the ability to perform direct comparisons of therapeutic efficacy between investigational treatments, presenting ongoing challenges for regulatory assessment and clinical decision-making in EPP management.

The Unmet Needs in Erythropoietic Protoporphyria Treatment

Current erythropoietic protoporphyria (EPP) treatment faces significant limitations across approved, historical, and investigational therapies. While afamelanotide represents a breakthrough as the first approved treatment, substantial gaps remain in addressing the full spectrum of patient needs. Multiple investigational approaches show promise but present their own challenges in development and evaluation.

• Afamelanotide does not address the underlying disease mechanism of EPP and is currently only approved for adult patients, leaving children and adolescents without treatment options, while causing diffuse hyperpigmentation in almost all patients

• Historical treatments lack proven efficacy, with insufficient data to demonstrate effectiveness of beta-carotene, NAC, and vitamin C, where four of five well-designed studies suggested lack of efficacy and results were inversely correlated with study quality

• Clinical trial design limitations prevent direct comparison of new investigational therapies (dersimelagon, bitopertin, cimetidine), as they are evaluated against placebo or baseline rather than against afamelanotide, with differences in outcome measures and patient populations

• Safety and efficacy profiles require further characterization for investigational treatments, with dersimelagon showing promise as an oral MC1R agonist but causing hyperpigmentation and lentigo in Phase 1 studies, while larger-scale studies are needed to confirm long-term benefits

• Pediatric treatment remains an unmet need across all current approaches, with no approved therapies for children and adolescents, though investigational treatments could potentially offer benefits for this population and prevention of disease complications

APOLLO: Designing a Path to Bitopertin's Full Approval

A clinical trial conducted from January 2023 to August 2024 evaluated an oral therapy to improve sunlight tolerance in adults with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). The study utilized comprehensive patient-reported outcome measures to assess treatment efficacy across multiple domains of disease impact. Additionally, afamelanotide has demonstrated efficacy in randomized controlled trials and received FDA approval for increasing pain-free sunlight exposure in adult EPP patients.

Bitopertin's Resubmission: A Pivotal Moment for EPP Therapy

Disc Medicine's recent agreement with the FDA to resubmit bitopertin for erythropoietic protoporphyria (EPP) marks a significant turning point for this ultra-rare genetic disorder. Following a previous rejection, this development signals a clearer regulatory path, with a decision anticipated by mid-2027, and underscores the potential for a novel therapeutic approach.

Bitopertin, a glycine transporter 1 (GlyT1) inhibitor, offers a compelling mechanism of action by directly targeting the underlying pathophysiology of EPP. By reducing the accumulation of protoporphyrin IX (PPIX), the compound aims to be disease-modifying, a crucial distinction from existing symptomatic treatments. Clinical data from Phase 2 studies, such as AURORA and BEACON, have demonstrated significant, dose-dependent reductions in whole-blood PPIX levels, alongside improvements in sunlight tolerance and patient quality of life. These findings, coupled with a favorable safety profile, position bitopertin as a promising oral option for patients.

Strategically, this represents a successful repurposing of a compound initially developed for schizophrenia, showcasing the value of exploring new indications for assets with known mechanisms. For EPP, where afamelanotide is the only approved treatment and is limited to adults, bitopertin could address a critical unmet need, particularly for children and adolescents. However, the landscape is not without its complexities. A key challenge lies in the lack of direct comparative data against afamelanotide, as current trials are placebo-controlled and utilize different outcome measures. Furthermore, while short-term safety and efficacy appear favorable, the long-term impact, especially on preventing chronic liver disease, requires further characterization. The FDA's prior concerns regarding surrogate endpoint adequacy also highlight the ongoing need for robust validation of clinical endpoints in rare disease development. Despite these considerations, the potential for an oral, disease-modifying therapy for EPP represents a substantial step forward for patients and the broader rare disease community.